Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.
Coltelli L, Fontana A, Lucchesi S, Ginocchi L, Bocci G, Filidei M, Scalese M, Arrighi G, Finale C, Marcucci L, Goletti O, Salvadori B, Ferrarini I, Bona E, Falcone A, Allegrini G. Coltelli L, et al. Among authors: lucchesi s. Breast. 2017 Feb;31:186-191. doi: 10.1016/j.breast.2016.11.006. Epub 2016 Nov 23. Breast. 2017. PMID: 27886643 Clinical Trial.
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G. Allegrini G, et al. Among authors: lucchesi s. Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140. Pharmacogenomics. 2014. PMID: 25521357 Clinical Trial.
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G. Allegrini G, et al. Among authors: lucchesi s. Angiogenesis. 2012 Jun;15(2):275-86. doi: 10.1007/s10456-012-9260-6. Epub 2012 Mar 2. Angiogenesis. 2012. PMID: 22382585 Free PMC article.
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G. Di Desidero T, et al. Among authors: lucchesi s. Invest New Drugs. 2016 Dec;34(6):760-770. doi: 10.1007/s10637-016-0385-0. Epub 2016 Aug 24. Invest New Drugs. 2016. PMID: 27557783 Clinical Trial.
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A, Galli L, Di Desidero T, Fioravanti A, Lucchesi S, Coltelli L, Ginocchi L, Allegrini G, Danesi R, Falcone A, Bocci G. Solini A, et al. Among authors: lucchesi s. Oncotarget. 2015 Oct 6;6(30):28743-54. doi: 10.18632/oncotarget.4926. Oncotarget. 2015. PMID: 26337470 Free PMC article.
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F. Mazzoni F, et al. Among authors: lucchesi s. Lung Cancer. 2013 Nov;82(2):288-93. doi: 10.1016/j.lungcan.2013.08.018. Epub 2013 Sep 3. Lung Cancer. 2013. PMID: 24045016 Clinical Trial.
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: lucchesi s. PLoS One. 2013 Jul 4;8(7):e66774. doi: 10.1371/journal.pone.0066774. Print 2013. PLoS One. 2013. PMID: 23861747 Free PMC article.
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant.
Pastore G, Polvere J, Fiorino F, Lucchesi S, Montesi G, Rancan I, Zirpoli S, Lippi A, Durante M, Fabbiani M, Tumbarello M, Montagnani F, Medaglini D, Ciabattini A. Pastore G, et al. Among authors: lucchesi s. Expert Rev Vaccines. 2024 Jan-Dec;23(1):432-444. doi: 10.1080/14760584.2024.2333952. Epub 2024 Apr 2. Expert Rev Vaccines. 2024. PMID: 38517153 Free article.
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, Clements TL, Jonsdottir HR, Nakka SS, Rothenberger S, Kremsner P, Züst R, Medaglini D, Ottenhoff T, Harandi AM, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Clin Microbiol Infect. 2023 Dec;29(12):1587-1594. doi: 10.1016/j.cmi.2023.08.026. Epub 2023 Sep 3. Clin Microbiol Infect. 2023. PMID: 37661067
46 results